Search

Displaying results 1261 - 1270 of 10000 in total
  1. Drug

    Human thrombin

    go.drugbank.com/drugs/DB11571
    ApprovedInvestigational

    Chinese hamster ovary cell line [FDA Label]. … In particular, while human thrombin products are made from pooled human source plasma, recombinant thrombin is a human coagulation protein produced via recombinant DNA technology from a genetically modified

  2. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone.

    Synonyms: N-Cyclopropylmethylnoroxymorphone, N-Cyclopropylmethyl-14-hydroxydihydromorphinoneMixtures: Troxyca ER, Troxyca ER
  3. Drug

    Lumefantrine

    go.drugbank.com/drugs/DB06708
    ApprovedInvestigational

    Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

    Mixtures: COARTEM® TABLETAS DISPERSABLES 20/120MG
  4. Drug

    Moxidectin

    go.drugbank.com/drugs/DB11431
    ApprovedInvestigationalVet approved

    It was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of the milbemycin class. … [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970]

    Mixtures: Advocate Spot-on Solution for Small Dogs, Advocate Spot-on Solution for Large DogsCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … metastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with [fulvestrant].

  6. Drug

    Ergocalciferol

    go.drugbank.com/drugs/DB00153
    ApprovedInvestigationalNutraceutical

    Ergocalciferol is an inactivated vitamin D analog.[A177526] It is synthesized by some plants in the presence of UVB light. … Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932.

    Mixtures: Formula EC, Vitamines Pour Bebes Et Enfants
  7. Drug

    Sodium hydroxide

    go.drugbank.com/drugs/DB11151
    Approved

    The use of this compound has been shown to effectively reduce prion levels in an in vitro inactivation assay [A32334]. … Interestingly, sodium hydroxide has been studied for its use in the treatment of prion disease (as occurs in mad cow disease and kuru).

    Mixtures: AMINOPLASMAL® 10% E, AMINOPLASMAL® 10% ECategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Triprolidine

    go.drugbank.com/drugs/DB00427
    Approved

    First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.

    Mixtures: COUGH-EN LINCTUS, COUGH-EN LINCTUSSynonyms: (E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine, trans-1-(2-pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene
  9. Drug

    Camphor

    go.drugbank.com/drugs/DB01744
    ApprovedInvestigationalWithdrawn

    Camphor is a bicyclic monoterpene ketone found widely in plants, especially _Cinnamomum camphora_. It is used topically as a skin antipruritic and as an anti-infective agent. … It appears in the list of drug products withdrawn or removed from the market for safety or effectiveness.

    Mixtures: EZ-Relief, Thera Derm Roll OnProducts: Flex24 Pain Pen, Dr Bob Arnots Pain Pen
  10. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed. … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible